| HOME >> BIOLOGY >> TECHNOLOGY |
Shares trading under IVOB symbol on OTCBB
BEVERLY, Mass., Feb. 25 /PRNewswire-FirstCall/ -- INVO Bioscience, Inc. ("INVO Bioscience" or "the company"), focused on creating simplified, lower cost treatment option for patients diagnosed with infertility, announced the closing of its reverse merger with Emy's Salsa Aji Distribution Company, Inc. (OTC Bulletin Board: EMYS.OB). Through this transaction, INVO Bioscience, formerly BioXcell becomes a public reporting company and its common stock is listed on the OTCBB under the newly-assigned symbol (OTC Bulletin Board: IVOB). The INVO Bioscience executive team will operate the new company focusing on INVOcell sales globally.
"This is a significant step in the growth of our company," said Kathleen Karloff, Chief Executive Officer of INVO Bioscience. "We are now positioned to execute our vision of providing an innovative, more affordable infertility treatment option to the millions of infertile men and women around the world".
"The INVOcell is a novel medical device that enables egg fertilization and early embryo development in the woman's vaginal cavity. The INVO Procedure will be an important option for patients who cannot afford conventional infertility treatments, enabling more patients to seek treatment and build families," added Claude Ranoux, MD, MS, Founder, President and Chief Scientist, INVO Bioscience.
For additional information about this transaction, see the company's Current Report on Form 8-K/A filed with the Securities and Exchange Commission on February 17, 2009 at www.sec.gov.
About the INVOcell Procedure
The INVOcell and INVO Procedure combine a natural or mild stimulation infertility treatment cycle, using lower amounts of injectable fertility hormones than used in traditional IVF(in vitro fertilization), with intra-vaginal incubation
'/>"/>
| SOURCE INVO Bioscience, Inc. Copyright©2009 PR Newswire. All rights reserved |